Novavax Financial Statements From 2010 to 2024
| NVAX Stock | USD 4.15 0.04 0.95% |
Gross Profit -156 M | Profit Margin (0.55) | Market Capitalization 586.4 M | Enterprise Value Revenue 0.4678 | Revenue 983.7 M |
Novavax Total Revenue |
|
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many exotic indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0079 or Days Sales Outstanding of 97.33. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
Novavax | Select Account or Indicator |
Novavax Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novavax Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novavax Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novavax Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novavax Fundamental Market Drivers
| Forward Price Earnings | 1.7816 | |
| Cash And Short Term Investments | 578.9 M |
Novavax Upcoming Events
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
About Novavax Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Novavax income statement, its balance sheet, and the statement of cash flows. Novavax investors use historical funamental indicators, such as Novavax's revenue or net income, to determine how well the company is positioned to perform in the future. Although Novavax investors may use each financial statement separately, they are all related. The changes in Novavax's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novavax's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novavax Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novavax. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 241.3 M | 140.2 M | |
| Total Revenue | 983.7 M | 1 B | |
| Cost Of Revenue | 279.5 M | 293.4 M | |
| Stock Based Compensation To Revenue | 0.09 | 0.08 | |
| Sales General And Administrative To Revenue | 0.35 | 0.33 | |
| Research And Ddevelopement To Revenue | 0.67 | 0.63 | |
| Capex To Revenue | (0.06) | (0.06) | |
| Revenue Per Share | 9.76 | 10.25 | |
| Ebit Per Revenue | (0.42) | (0.44) |
Novavax Investors Sentiment
The influence of Novavax's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novavax. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novavax's public news can be used to forecast risks associated with an investment in Novavax. The trend in average sentiment can be used to explain how an investor holding Novavax can time the market purely based on public headlines and social activities around Novavax. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novavax's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novavax's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novavax's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novavax.
Novavax Implied Volatility | 105.22 |
Novavax's implied volatility exposes the market's sentiment of Novavax stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novavax's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novavax stock will not fluctuate a lot when Novavax's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novavax in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novavax's short interest history, or implied volatility extrapolated from Novavax options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Novavax Correlation against competitors. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.41) | Revenue Per Share 9.762 | Quarterly Revenue Growth (0.18) | Return On Assets (0.17) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.